• Je něco špatně v tomto záznamu ?

Antioxidant action of xanthine oxidase inhibitor febuxostat protects the liver and blood vasculature in SHRSP5/Dmcr rats

M. Kakimoto, M. Fujii, I. Sato, K. Honma, H. Nakayama, S. Kirihara, T. Fukuoka, S. Ran, S. Hirohata, K. Kitamori, S. Yamamoto, S. Watanabe

. 2023 ; 21 (2) : 80-90. [pub] 20230522

Jazyk angličtina Země Česko

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc23008971

BACKGROUND: Xanthine oxidase (XO) generates reactive oxygen species during uric acid production. Therefore, XO inhibitors, which suppress oxidative stress, may effectively treat non-alcoholic steatohepatitis (NASH) and atherosclerosis via uric acid reduction. In this study, we examined the antioxidant effect of the XO inhibitor febuxostat on NASH and atherosclerosis in stroke-prone spontaneously hypertensive 5 (SHRSP5/Dmcr) rats. METHODS: SHRSP5/Dmcr rats were divided into three groups: SHRSP5/Dmcr + high-fat and high-cholesterol (HFC) diet [control group, n = 5], SHRSP5/Dmcr + HFC diet + 10% fructose (40 ml/day) [fructose group, n = 5], and SHRSP5/Dmcr + HFC diet + 10% fructose (40 ml/day) + febuxostat (1.0 mg/kg/day) [febuxostat group, n = 5]. Glucose and insulin resistance, blood biochemistry, histopathological staining, endothelial function, and oxidative stress markers were evaluated. RESULTS: Febuxostat reduced the plasma uric acid levels. Oxidative stress-related genes were downregulated, whereas antioxidant factor-related genes were upregulated in the febuxostat group compared with those in the fructose group. Febuxostat also ameliorated inflammation, fibrosis, and lipid accumulation in the liver. Mesenteric lipid deposition decreased in the arteries, and aortic endothelial function improved in the febuxostat group. CONCLUSIONS: Overall, the XO inhibitor febuxostat exerted protective effects against NASH and atherosclerosis in SHRSP5/Dmcr rats.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23008971
003      
CZ-PrNML
005      
20230802075152.0
007      
ta
008      
230707s2023 xr da f 000 0|eng||
009      
AR
024    7_
$a 10.32725/jab.2023.009 $2 doi
035    __
$a (PubMed)37376883
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xr
100    1_
$a Kakimoto, Mai $u Okayama University, Graduate School of Health Sciences, Department of Medical Technology, 2-5-1, Shikata-cho, Kita-ku, Okayama-shi, Okayama 700-8558, Japan
245    10
$a Antioxidant action of xanthine oxidase inhibitor febuxostat protects the liver and blood vasculature in SHRSP5/Dmcr rats / $c M. Kakimoto, M. Fujii, I. Sato, K. Honma, H. Nakayama, S. Kirihara, T. Fukuoka, S. Ran, S. Hirohata, K. Kitamori, S. Yamamoto, S. Watanabe
520    9_
$a BACKGROUND: Xanthine oxidase (XO) generates reactive oxygen species during uric acid production. Therefore, XO inhibitors, which suppress oxidative stress, may effectively treat non-alcoholic steatohepatitis (NASH) and atherosclerosis via uric acid reduction. In this study, we examined the antioxidant effect of the XO inhibitor febuxostat on NASH and atherosclerosis in stroke-prone spontaneously hypertensive 5 (SHRSP5/Dmcr) rats. METHODS: SHRSP5/Dmcr rats were divided into three groups: SHRSP5/Dmcr + high-fat and high-cholesterol (HFC) diet [control group, n = 5], SHRSP5/Dmcr + HFC diet + 10% fructose (40 ml/day) [fructose group, n = 5], and SHRSP5/Dmcr + HFC diet + 10% fructose (40 ml/day) + febuxostat (1.0 mg/kg/day) [febuxostat group, n = 5]. Glucose and insulin resistance, blood biochemistry, histopathological staining, endothelial function, and oxidative stress markers were evaluated. RESULTS: Febuxostat reduced the plasma uric acid levels. Oxidative stress-related genes were downregulated, whereas antioxidant factor-related genes were upregulated in the febuxostat group compared with those in the fructose group. Febuxostat also ameliorated inflammation, fibrosis, and lipid accumulation in the liver. Mesenteric lipid deposition decreased in the arteries, and aortic endothelial function improved in the febuxostat group. CONCLUSIONS: Overall, the XO inhibitor febuxostat exerted protective effects against NASH and atherosclerosis in SHRSP5/Dmcr rats.
650    _2
$a krysa rodu Rattus $7 D051381
650    _2
$a zvířata $7 D000818
650    12
$a nealkoholová steatóza jater $x farmakoterapie $x patologie $7 D065626
650    _2
$a antioxidancia $x farmakologie $x terapeutické užití $7 D000975
650    _2
$a febuxostat $x farmakologie $x terapeutické užití $7 D000069465
650    _2
$a xanthinoxidasa $7 D014969
650    _2
$a kyselina močová $7 D014527
650    _2
$a potkani inbrední SHR $7 D011918
650    _2
$a dieta s vysokým obsahem tuků $7 D059305
650    _2
$a inhibitory enzymů $7 D004791
650    12
$a ateroskleróza $x farmakoterapie $7 D050197
650    _2
$a lipidy $7 D008055
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Fujii, Moe $u Okayama University, Graduate School of Health Sciences, Department of Medical Technology, 2-5-1, Shikata-cho, Kita-ku, Okayama-shi, Okayama 700-8558, Japan
700    1_
$a Sato, Ikumi $u Okayama University, Graduate School of Health Sciences, Department of Medical Technology, 2-5-1, Shikata-cho, Kita-ku, Okayama-shi, Okayama 700-8558, Japan
700    1_
$a Honma, Koki $u Okayama University, Graduate School of Health Sciences, Department of Medical Technology, 2-5-1, Shikata-cho, Kita-ku, Okayama-shi, Okayama 700-8558, Japan
700    1_
$a Nakayama, Hinako $u Okayama University, Graduate School of Health Sciences, Department of Medical Technology, 2-5-1, Shikata-cho, Kita-ku, Okayama-shi, Okayama 700-8558, Japan
700    1_
$a Kirihara, Sora $u Okayama University, Graduate School of Health Sciences, Department of Medical Technology, 2-5-1, Shikata-cho, Kita-ku, Okayama-shi, Okayama 700-8558, Japan
700    1_
$a Fukuoka, Taketo $u Okayama University, Faculty of Health Sciences, Department of Medical Technology, 2-5-1, Shikata-cho, Kita-ku, Okayama-shi, Okayama, 700-8558, Japan
700    1_
$a Ran, Shang $u Okayama University, Graduate School of Health Sciences, Department of Medical Technology, 2-5-1, Shikata-cho, Kita-ku, Okayama-shi, Okayama 700-8558, Japan
700    1_
$a Hirohata, Satoshi $u Okayama University, Academic Field of Health Science, 2-5-1, Shikata-cho, Kita-ku, Okayama-shi, Okayama, 700-8558, Japan
700    1_
$a Kitamori, Kazuya $u Kinjo Gakuin University, College of Human Life and Environment, 2-1723, Omori, Moriyama-ku, Nagoya-shi, Aichi, 463-8521, Japan
700    1_
$a Yamamoto, Shusei $u Okayama University, Graduate School of Health Sciences, Department of Medical Technology, 2-5-1, Shikata-cho, Kita-ku, Okayama-shi, Okayama 700-8558, Japan $u Okayama University, Academic Field of Health Science, 2-5-1, Shikata-cho, Kita-ku, Okayama-shi, Okayama, 700-8558, Japan
700    1_
$a Watanabe, Shogo $u Okayama University, Academic Field of Health Science, 2-5-1, Shikata-cho, Kita-ku, Okayama-shi, Okayama, 700-8558, Japan
773    0_
$w MED00012667 $t Journal of applied biomedicine $x 1214-0287 $g Roč. 21, č. 2 (2023), s. 80-90
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37376883 $y Pubmed
910    __
$a ABA008 $b B 2301 $c 1249 $y p $z 0
990    __
$a 20230707 $b ABA008
991    __
$a 20230802075148 $b ABA008
999    __
$a ok $b bmc $g 1964389 $s 1195234
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 21 $c 2 $d 80-90 $e 20230522 $i 1214-0287 $m Journal of Applied Biomedicine $n J. Appl. Biomed. (Čes. Budějovice Print) $x MED00012667
LZP    __
$b NLK198 $a Pubmed-20230707

Najít záznam

Citační ukazatele

Možnosti archivace